Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy

Imatinib is the most commonly used drug in chronic myeloid leukemia (CML) patients worldwide. [1] Frontline treatment of newly diagnosed patients with imatinib 400  mg daily determined a 10-year survival rate around 82-83% [2], close to that of the general population [3]. In early 2017 a generic formulation of imatinib was introduced in the Italian market and patients switched from branded (i.e. Glivec®, Novartis) to the generic one upon requirement by regi onal health authorities.

Source: Leukemia Research - October 1, 2018 Category: Hematology Authors: Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, Maria Cristina Miggiano, Marco Danini, Claudia Minotto, Davide Griguolo, Luciana Marin, Luca Frison, Fabio D ’Amore, Marco Basso, Roberto Sartori, Martina Tinelli, Manuela Stulle, Stefania Fortuna, Source Type: research